A Pooled Analysis to Compare the Clinical Characteristics of Human Papillomavirus-positive and -Negative Cervical Precancers.


Journal

Cancer prevention research (Philadelphia, Pa.)
ISSN: 1940-6215
Titre abrégé: Cancer Prev Res (Phila)
Pays: United States
ID NLM: 101479409

Informations de publication

Date de publication:
10 2020
Historique:
received: 17 04 2020
revised: 16 06 2020
accepted: 02 07 2020
pubmed: 14 7 2020
medline: 5 10 2021
entrez: 14 7 2020
Statut: ppublish

Résumé

Given that high-risk human papillomavirus (HPV) is the necessary cause of virtually all cervical cancer, the clinical meaning of HPV-negative cervical precancer is unknown. We, therefore, conducted a literature search in Ovid MEDLINE, PubMed Central, and Google Scholar to identify English-language studies in which (i) HPV-negative and -positive, histologically confirmed cervical intraepithelial neoplasia grade 2 or more severe diagnoses (CIN2+) were detected and (ii) summarized statistics or deidentified individual data were available to summarize proportions of biomarkers indicating risk of cancer. Nineteen studies including 3,089 (91.0%) HPV-positive and 307 (9.0%) HPV-negative CIN2+ were analyzed. HPV-positive CIN2+ (vs. HPV-negative CIN2+) was more likely to test positive for biomarkers linked to cancer risk: a study diagnosis of CIN3+ (vs. CIN2; 18 studies; 0.56 vs. 0.24;

Identifiants

pubmed: 32655005
pii: 1940-6207.CAPR-20-0182
doi: 10.1158/1940-6207.CAPR-20-0182
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

829-840

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Philip E Castle (PE)

Albert Einstein College of Medicine, Department of Epidemiology and Population Health, Bronx, New York. philip.castle@nih.gov.

Amanda J Pierz (AJ)

Albert Einstein College of Medicine, Department of Epidemiology and Population Health, Bronx, New York.

Rachael Adcock (R)

Queen Mary University of London, Centre for Cancer Prevention, London, United Kingdom.

Shagufta Aslam (S)

Roche Molecular Diagnostics, Pleasanton, California.

Partha S Basu (PS)

International Agency for Research on Cancer, Screening Group, Lyon, France.

Jerome L Belinson (JL)

Preventive Oncology International and the Cleveland Clinic, Cleveland, Ohio.

Jack Cuzick (J)

Queen Mary University of London, Centre for Cancer Prevention, London, United Kingdom.

Mariam El-Zein (M)

Division of Cancer Epidemiology, McGill University, Montréal, Quebec, Canada.

Catterina Ferreccio (C)

Advanced Center for Chronic Diseases, ACCDiS, Santiago, Chile.
Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Cynthia Firnhaber (C)

School of Medicine, University of Colorado, Aurora, Colorado.

Eduardo L Franco (EL)

Division of Cancer Epidemiology, McGill University, Montréal, Quebec, Canada.

Patti E Gravitt (PE)

Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland.

Sandra D Isidean (SD)

Division of Cancer Epidemiology, McGill University, Montréal, Quebec, Canada.

John Lin (J)

HPV Research Group, University of Washington, Seattle, Washington.

Salaheddin M Mahmud (SM)

Rady Faculty of Health Sciences, Department of Community Health, University of Manitoba, Max Rady College of Medicine, Winnipeg, Manitoba, Canada.

Joseph Monsonego (J)

Institute of the Cervix, Federation Mutualiste Parisienne, Paris, France.

Richard Muwonge (R)

International Agency for Research on Cancer, Screening Group, Lyon, France.

Samuel Ratnam (S)

Division of Cancer Epidemiology, McGill University, Montréal, Quebec, Canada.

Mahboobeh Safaeian (M)

Roche Molecular Diagnostics, Pleasanton, California.

Mark Schiffman (M)

Division of Cancer Epidemiology & Genetics, NIH, NCI, Bethesda, Maryland.

Jennifer S Smith (JS)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Avril Swarts (A)

Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa.

Thomas C Wright (TC)

Department of Pathology and Cell Biology, Columbia University, New York, New York.

Vanessa Van De Wyngard (V)

Advanced Center for Chronic Diseases, ACCDiS, Santiago, Chile.
Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Long Fu Xi (LF)

HPV Research Group, University of Washington, Seattle, Washington.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH